Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Venlafaxine
Generic Name
Venlafaxine
Active Ingredient
VenlafaxineCategory
Other
Salt Form
Hydrochloride
Variants
93
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 75 mg/1 | TABLET | ORAL | 63629-3324 |
| 37.5 mg/1 | TABLET | ORAL | 68001-158 |
| 75 mg/1 | TABLET | ORAL | 68001-160 |
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Venlafaxine, you must consult a qualified healthcare professional.
| 75 mg/1 | TABLET | ORAL | 68084-856 |
| 75 mg/1 | TABLET | ORAL | 68382-021 |
| 75 mg/1 | TABLET, EXTENDED RELEASE | ORAL | 70518-4566 |
| 225 mg/1 | TABLET, EXTENDED RELEASE | ORAL | 70710-1352 |
| 75 mg/1 | TABLET | ORAL | 71209-028 |
| 150 mg/1 | TABLET, COATED | ORAL | 72241-076 |
| 75 mg/1 | TABLET | ORAL | 50090-2408 |
| 75 mg/1 | TABLET | ORAL | 50090-4715 |
| 37.5 mg/1 | TABLET | ORAL | 51407-454 |
+ 38 more variants
Detailed information about Venlafaxine
Venlafaxine is a potent Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) used to treat major depressive disorder, generalized anxiety, and panic disorders. It works by balancing neurotransmitters in the brain to improve mood and energy levels.
Dosage for venlafaxine must be individualized based on the specific condition being treated and the patient's response to the medication. Healthcare providers typically follow a 'start low and go slow' approach to minimize side effects.
Venlafaxine is not FDA-approved for use in pediatric patients (children and adolescents under 18 years of age). Clinical trials in pediatric populations have not consistently demonstrated efficacy for MDD or GAD. Furthermore, there is an increased risk of suicidal ideation and behavior in children and young adults taking antidepressants. If a specialist determines that venlafaxine is necessary for a minor, they will provide highly specific, off-label dosing and require intensive monitoring.
For patients with mild to moderate kidney impairment (creatinine clearance of 30–70 mL/min), the total daily dose should be reduced by 25% to 50%. For patients undergoing hemodialysis, the dose should be reduced by 50% and administered only after the dialysis session is completed.
In patients with mild to moderate liver impairment (Child-Pugh Class A or B), the daily dose should typically be reduced by 50%. Because the clearance of venlafaxine is significantly reduced in these patients, individualization of the dose is critical. It is generally not recommended for use in severe hepatic impairment unless the benefits clearly outweigh the risks.
While no specific starting dose adjustment is required solely based on age, caution is advised. Elderly patients are at a higher risk for hyponatremia (low blood sodium) and may have age-related declines in renal or hepatic function that necessitate slower titration.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up. Frequent missed doses can trigger withdrawal-like symptoms.
Signs of a venlafaxine overdose may include extreme drowsiness, rapid heart rate (tachycardia), seizures, vomiting, and changes in blood pressure. In severe cases, serotonin syndrome or cardiac arrhythmias may occur. If an overdose is suspected, contact emergency services or a poison control center immediately. Emergency treatment often involves gastric lavage, administration of activated charcoal, and intensive supportive care.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop the medication without medical guidance, as rapid changes can lead to severe side effects.
Side effects are most common during the first few weeks of treatment as the body adjusts to the medication. Many of these symptoms are transient and resolve over time.
Venlafaxine is a powerful medication that requires careful medical supervision. It is not suitable for everyone, and patients must be screened for underlying conditions such as bipolar disorder, heart disease, or narrow-angle glaucoma before starting therapy. Patients should be aware that the full therapeutic effect of the drug may take 4 to 8 weeks to manifest.
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.
There are specific circumstances where venlafaxine must NEVER be used because the risks far outweigh any potential benefit:
These are conditions where the drug should be used with extreme caution and only after a thorough risk-benefit analysis by a specialist:
Venlafaxine is classified as Pregnancy Category C (under the older FDA system). There are no adequate and well-controlled studies in pregnant women. Animal studies have shown some evidence of fetal harm at high doses.
Venlafaxine and its active metabolite, ODV, are excreted into human breast milk. Studies have shown that the infant dose is approximately 6% to 9% of the maternal weight-adjusted dose. While many infants show no adverse effects, there are reports of poor feeding, irritability, and sleep disturbances. The decision to breastfeed while taking venlafaxine should be made in consultation with a pediatrician, weighing the benefits of breastfeeding against the potential risks of infant drug exposure.
Venlafaxine is a potent inhibitor of the neuronal reuptake of serotonin (5-HT) and norepinephrine (NE). It also weakly inhibits the reuptake of dopamine. Its primary mechanism involves binding to the serotonin transporter (SERT) and the norepinephrine transporter (NET). By blocking these transporters, venlafaxine increases the dwell time of neurotransmitters in the synapse, enhancing postsynaptic receptor activation. Venlafaxine has virtually no affinity for muscarinic, histaminergic, or alpha-1 adrenergic receptors, which explains why it lacks the sedative and anticholinergic side effects common to older tricyclic antidepressants.
The pharmacodynamic effect of venlafaxine is highly dependent on the dose. At 75 mg/day, the drug primarily affects serotonin. At doses of 150 mg/day and above, the effect on norepinephrine becomes clinically evident. This dual action is thought to be responsible for its efficacy in treatment-resistant depression. The onset of the antidepressant effect typically occurs within 2 weeks, but the full clinical response may take 4 to 8 weeks.
| Parameter | Value |
Common questions about Venlafaxine
Venlafaxine is a prescription medication primarily used to treat Major Depressive Disorder (MDD) and various anxiety disorders. It is FDA-approved for Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder. By balancing serotonin and norepinephrine in the brain, it helps improve mood, sleep, and energy levels while reducing feelings of fear or panic. Some doctors also prescribe it off-label for menopause-related hot flashes or chronic nerve pain. It is available in both immediate-release and extended-release formulations to suit different treatment plans.
The most common side effects of venlafaxine include nausea, dry mouth, dizziness, excessive sweating, and sleepiness. Many patients also report insomnia or vivid dreams during the first few weeks of treatment. Sexual side effects, such as decreased libido or difficulty reaching orgasm, are also relatively common. Most of these symptoms are mild to moderate and tend to decrease as your body adjusts to the medication. However, if these effects persist or become bothersome, you should consult your healthcare provider about a possible dose adjustment.
It is generally recommended that you avoid drinking alcohol while taking venlafaxine. Alcohol is a central nervous system depressant that can worsen the symptoms of depression and anxiety, effectively counteracting the benefits of the medication. Furthermore, combining alcohol with venlafaxine can increase the risk of side effects like extreme drowsiness, dizziness, and impaired coordination. There is also a potential for increased strain on the liver when alcohol and antidepressants are processed simultaneously. Always discuss your alcohol consumption habits with your doctor before starting this medication.
Venlafaxine should only be used during pregnancy if the potential benefits to the mother outweigh the potential risks to the fetus. It is classified as Category C, meaning animal studies have shown some risks, but human data is limited. Taking venlafaxine during the third trimester may lead to withdrawal symptoms or respiratory distress in the newborn, a condition sometimes called neonatal adaptation syndrome. However, untreated depression during pregnancy also carries significant risks for both the mother and the baby. Pregnant women or those planning to become pregnant should have a detailed discussion with their obstetrician and psychiatrist.
While some patients may notice slight improvements in sleep or energy within the first 1 to 2 weeks, the full antidepressant or anti-anxiety effects of venlafaxine usually take longer. Most clinical guidelines suggest that it takes 4 to 8 weeks of consistent use at a therapeutic dose to realize the medication's full benefits. It is important to continue taking the medication even if you do not feel better immediately. If you have not noticed any improvement after 6 weeks, your doctor may consider increasing your dose or switching to a different medication. Never stop taking the drug early without medical advice.
No, you should never stop taking venlafaxine suddenly. Abruptly discontinuing this medication can lead to 'Discontinuation Syndrome,' which includes symptoms like dizziness, nausea, headache, irritability, and 'brain zaps' (sensations resembling electric shocks in the head). Because venlafaxine has a relatively short half-life, these symptoms can appear within hours of a missed dose. To stop the medication safely, your doctor will provide a tapering schedule to gradually reduce your dose over several weeks or months. This allows your brain chemistry to adjust slowly and minimizes withdrawal symptoms.
If you miss a dose of venlafaxine, you should take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular timing. You should never take two doses at once to make up for a missed one, as this increases the risk of side effects or toxicity. Because venlafaxine withdrawal symptoms can start quickly, missing a dose may cause you to feel dizzy or nauseous. If you frequently forget your medication, consider using a pill organizer or setting a daily alarm on your phone.
The effect of venlafaxine on weight can vary significantly between individuals. In short-term clinical trials, many patients actually experienced a decrease in appetite and slight weight loss. However, with long-term use, some patients may experience weight gain, which is a common trend across many antidepressant medications. This weight gain may be due to improved appetite as depression resolves or changes in metabolism. If you are concerned about weight changes, your doctor can help you develop a plan involving diet and exercise or monitor your metabolic health during treatment.
Venlafaxine can interact with many other drugs, some of which can cause serious health problems. It should never be taken with Monoamine Oxidase Inhibitors (MAOIs), as this can lead to a fatal reaction. It also interacts with other serotonergic drugs (like triptans for migraines or tramadol for pain), increasing the risk of serotonin syndrome. Additionally, it may increase the risk of bleeding if taken with blood thinners like warfarin or NSAIDs like ibuprofen. Always provide your healthcare provider with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking.
Yes, venlafaxine is widely available as a generic medication in both immediate-release and extended-release forms. Generic versions are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug (Effexor or Effexor XR). Generic medications are typically much more affordable than brand-name versions and are covered by most insurance plans. While the inactive ingredients (like fillers or dyes) may differ between generic manufacturers, the clinical effect should be identical. Consult your pharmacist if you have questions about specific generic brands.
Other drugs with the same active ingredient (Venlafaxine)
> Warning: Stop taking Venlafaxine and call your doctor immediately or seek emergency care if you experience any of the following:
With prolonged use, some patients may experience persistent sexual dysfunction or weight changes. There is also a risk of developing sustained hypertension, which requires regular monitoring by a healthcare provider. Long-term use should not be discontinued abruptly due to the risk of Discontinuation Syndrome.
Suicidality and Antidepressant Drugs: The FDA has issued a black box warning for all antidepressants, including venlafaxine. In short-term studies, antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18–24) with MDD and other psychiatric disorders. This risk was not seen in patients over age 24. Families and caregivers should monitor patients of all ages for worsening of depression, suicidal thoughts, or unusual changes in behavior, especially during the first few months of treatment or during dose changes.
Report any unusual symptoms or side effects to your healthcare provider promptly. Most side effects can be managed with dose adjustments or supportive care.
Venlafaxine may impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that the medication does not adversely affect their ability to engage in such activities.
Patients should be advised to avoid alcohol while taking venlafaxine. Alcohol can exacerbate the sedative effects of the medication and may increase the risk of liver toxicity or worsen the underlying depressive or anxious condition.
Discontinuation Syndrome: Stopping venlafaxine abruptly can lead to severe withdrawal symptoms, often referred to as 'brain zaps.' Symptoms include dizziness, sensory disturbances (e.g., electric shock sensations), agitation, anxiety, nausea, and sweating. To prevent this, the dose must be tapered gradually over several weeks or months under the direction of a physician.
> Important: Discuss all your medical conditions, including a history of high blood pressure, heart problems, or seizures, with your healthcare provider before starting Venlafaxine.
Management Strategy: For most interactions, the management strategy involves either avoiding the combination, adjusting the dose, or performing frequent clinical monitoring for signs of toxicity or reduced efficacy.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to avoid dangerous interactions.
While venlafaxine is chemically distinct from SSRIs, patients who have experienced severe adverse reactions to other SNRIs (like duloxetine or desvenlafaxine) should be monitored closely, as they may share similar metabolic pathways or pharmacodynamic sensitivities.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of cardiovascular disease or glaucoma, before prescribing Venlafaxine.
Safety and effectiveness in the pediatric population have not been established. As noted in the Black Box Warning, there is an increased risk of suicidal ideation. Additionally, clinical trials have noted that pediatric patients taking venlafaxine may experience more frequent side effects like weight loss and increased blood pressure compared to adults.
In clinical trials, no overall differences in effectiveness or safety were observed between patients over 65 and younger patients. However, elderly individuals are more susceptible to:
For patients with a GFR (Glomerular Filtration Rate) between 10 and 70 mL/min, the dose should be reduced by 25% to 50%. Venlafaxine is not recommended for patients with end-stage renal disease (GFR < 10 mL/min) unless the benefits are substantial, as the half-life of the drug is significantly prolonged.
In patients with moderate hepatic impairment (Child-Pugh score 7-9), clearance is reduced by about 50%. These patients require a 50% dose reduction. For those with mild impairment, dose adjustments may not be strictly necessary but titration should be slower.
> Important: Special populations require individualized medical assessment and frequent monitoring to ensure safety and efficacy.
| Bioavailability | ~45% (due to extensive first-pass metabolism) |
| Protein Binding | 27% (Venlafaxine), 30% (ODV) |
| Half-life | 5 hours (Venlafaxine), 11 hours (ODV) |
| Tmax | 2 hours (IR), 5.5 hours (ER/XR) |
| Metabolism | Hepatic (CYP2D6 to active ODV, CYP3A4 to N-desmethyl) |
| Excretion | Renal 87%, Fecal ~5% |
Venlafaxine is the prototypical member of the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class. Other medications in this class include duloxetine (Cymbalta), desvenlafaxine (Pristiq), and milnacipran (Savella). While they share a similar mechanism, venlafaxine is unique in its dose-dependent shift from serotonergic to noradrenergic activity.